OCS+BLF--March-15  donate_button

Exciting developments from Viking Therapeutics

  Viking Therapeutics have announced results from a Proof-of-Concept study for their drug VK0214 which may be effective in reducing levels of Very Long Chain Fatty Acids in ALD http://ir.vikingtherapeutics.com/2017-10-04-Viking-Therapeutics-Announces-Top-Line-Results-from-Proof-of-Concept-Study-of-VK0214-in-In-Vivo-Model-of-X-Linked-Adrenoleukodystrophy-X-ALD.   Tim more…

Facebook